Medivir AB announced that the European Commission, in accordance with the opinion from the European Medicines Agency, has granted orphan medicinal product designation in the EU for MIV-818 for the treatment of patients with hepatocellular carcinoma, the most common type of primary liver cancer.
July 3, 2020
· 2 min read